Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of SPK-9001 (Fidanacogene Elaparvovec) in Hemophilia B
NCT02484092Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2015
- Primary completion
- Apr 2019
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of fidanacogene elaparvovec in hemophilia B (HB), sponsored by Pfizer. Started Nov 2015; status: completed.
02
Drugs
fidanacogene elaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT02484092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484092.